PIC Therapeutics is a Natick, Massachusetts biotechnology company developing small-molecule precision medicines that target cancer at the level of protein translation. Rather than chasing individual oncogenes one at a time, PIC modulates the Pre-Initiation Complex (PIC) and the translation factor eIF4E - a convergence point for many oncogenic signaling pathways - to selectively shut down the production of cancer-driving proteins while sparing healthy cells. Founded on the research of Harvard structural biologist Gerhard Wagner and led by CEO Katherine Bowdish, the company is advancing an allosteric eIF4E modulator toward first-in-human studies in drug-resistant metastatic breast cancer, backed by a $35M Series A led by OrbiMed.
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class oral small-molecule multi-kinase inhibitor that co-targets casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7/CDK9) - three master regulators of cancer cell survival and transcription. Founded by veteran biotech executive David N. Cook and emerging from stealth in March 2024 with $20M in Series A financing from Alta Partners, the company is advancing BTX-A51 through Phase 2a trials in relapsed/refractory acute myeloid leukemia and genetically-defined (GATA3-mutant) ER+/HER2- metastatic breast cancer.
David N. Cook, Ph.D., is the founder and CEO of Edgewood Oncology, a Boston-based virtual biotech advancing BTX-A51, a first-in-class small molecule that hits three master regulators of cancer at once (CK1 alpha, CDK7 and CDK9) to switch on programmed cell death. A chemist by training, with an A.B. from Harvard and a Ph.D. from UC Berkeley, Cook has spent roughly 30 years building venture-backed life sciences companies, helping raise more than $1 billion, leading three IPOs, orchestrating two acquisitions, and contributing to five commercialized products. He emerged Edgewood from stealth in March 2024 with a $20 million Series A led by Alta Partners.